目的 观察研究联合应用美多巴及脑深部电刺激治疗帕金森的临床疗效及安全性。方法 选取2014年3月至2016年5月 我科室收治诊断为帕金森患者50例，按随机数字表法分为观察组及对照组各25例，对照组患者给予美多巴口服常规 治疗，观察组在对照组常规治疗基础上加用脑深部电刺激治治疗，记录并分析治疗1月后两组患者帕金森病统一评 分量表及SCL-90因子分值情况。结果 （1）两组患者治疗后其UPDRS总分、UPDRSⅠ、UPDRS Ⅱ及UPDRS Ⅲ评分较治 疗均降低，且观察组UPDRS总分、UPDRSⅠ、UPDRSⅡ及UPDRSⅢ评分降低程度均明显大于对照组，比较差异间具有统 计学意义（P<0.05）；（2）两组患者治疗后其躯体、抑郁、焦虑、人际关系等SCL-90因子分值均较治疗前降低， 且观察组降低程度均明显低于对照组，比较差异间均均具有统计学意义（P<0.05）。结论 美多巴联合脑深部电刺 激治疗帕金森疗效肯定、确切，与单独口服美多巴常规治疗相比无明显不良反应，能显著提高怕帕金森患者生命生 活质量，值得临床进一步研究和应用。

Objective To study the clinical effect and safety of Madopar combined with deep brain stimulation in the treatment of Parkinson's disease. Methods From Mar. 2014 to May 2016, a total of 50 patients with Parkinson's disease in our department were taken as the clinical research objects, and they were randomly divided into observation group (25 cases) and control group (25 cases). Both groups were given conventional treatment of oral Madopar, besides, the observation group accepted additional deep brain stimulation. 1 month after treatment, the Unified Parkinson's Disease Rating Scale score and SCL-90 factor score in the two groups were recorded and analyzed. Results (1)The scores of UPDRS, UPDRSⅠ, UPDRS Ⅱ and UPDRS Ⅲ of the two groups were lower than those of the treatment, and the scores of UPDRS score, UPDRSⅠ, UPDRSⅡ and UPDRSⅢ scores in the observation group were significantly higher than those in the control group,the difference was statistically significant (P <0.05), (2)The scores of SCL-90 were significantly lower in the two groups after treatment than those before treatment,and the observation group were significantly lower than the control group,the difference was significant (P<0.05). Conclusion Compared with single oral Madopar treatment, Madopar combined with deep brain stimulation which has good and definite effect in the treatment of Parkinson's disease, and no obvious adverse reactions, can significantly improve patients' quality of life. Thus, it is worthy of further research and application in clinic.